查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1742555

呼吸道合胞病毒疫苗市场－全球产业分析、规模、份额、成长、趋势及预测（2025-2035）

Respiratory Syncytial Virus Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
出版日期: | 出版商: Transparency Market Research | 英文 175 Pages | 商品交期: 2-10个工作天内

价格

呼吸道合胞病毒疫苗市场-报告范围

TMR 的全球呼吸道合胞病毒疫苗市场报告研究了过去和当前的成长趋势及机会，旨在深入了解 2025 年至 2035 年预测期内的市场指标。该报告提供了 2019 年至 2035 年期间全球呼吸道合胞病毒疫苗市场的收入，以 2025 年为基准年，2035 年为预测年。报告中也提供了 2025 年至 2035 年全球呼吸道合胞病毒疫苗市场的年复合成长率(CAGR%)。

本报告经过广泛的调查后编写。主要研究工作包括：分析师对关键意见领袖、产业领导者和舆论领袖进行访谈。次要研究则参考了主要参与者的产品资料、年度报告、新闻稿和相关文件，以了解呼吸道合胞病毒疫苗市场。

市场概况
2024 年的市场价值 37亿美元
2035年的市场价值 159亿美元
复合年增长率 13.8%

本报告深入探讨了全球呼吸道合胞病毒疫苗市场的竞争格局。该报告确定了全球呼吸道合胞病毒疫苗市场的主要参与者，并根据不同特征对每家公司进行了分析。本报告分析了全球呼吸道合胞病毒疫苗市场参与者的概况、财务状况、近期发展和 SWOT 分析。

目录

第一章：前言

第二章：假设与研究方法

第三章：执行摘要：全球市场

第四章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2035年全球呼吸道合胞病毒疫苗市场分析与预测

第五章：关键见解

  • 主要国家医疗支出数据
  • 技术进步
  • 主要地区/国家的监管情况
  • 波特五力分析
  • PESTEL分析
  • 重要行业活动

第六章：全球市场分析与预测：依疫苗类型

  • 介绍与定义
  • 主要发现/进展
  • 2020-2035年疫苗类型市场价值预测
    • 重组/次单位疫苗
    • mAB注射液
    • mRV疫苗
    • 其他的
  • 疫苗类型市场吸引力

第七章：全球市场分析与预测：依年龄组

  • 介绍和定义
  • 主要发现/进展
  • 2020-2035年各年龄层市场价值预测
    • 成人及老年病学
    • 儿童和孕妇
  • 各年龄层的市场吸引力

第八章：全球市场分析与预测：依销售管道

  • 介绍和定义
  • 主要发现/进展
  • 2020 年至 2035 年按销售管道分類的市场价值预测
    • 零售药局
    • 医院药房
    • 其他的
  • 各销售通路的市场吸引力

第九章：全球市场分析与预测：按地区

  • 主要发现
  • 各地区市场价值预测
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 各地区市场吸引力

第十章：北美市场分析与预测

  • 我们
  • 加拿大

第 11 章：欧洲市场分析与预测

  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区

第十二章：亚太市场分析与预测

  • 中国
  • 日本
  • 印度
  • 澳洲和纽西兰
  • 亚太其他地区
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区

第 14 章：中东和非洲市场分析与预测

  • 海湾合作委员会国家
  • 南非
  • 中东和非洲其他地区

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 各公司市占率分析（2024 年）
  • 公司简介
    • GSK plc
    • Moderna, Inc.
    • Pfizer, Inc.
    • Sanofi
    • AstraZeneca
    • MAXVAX Biotechnology Limited
    • Guangzhou Patronus Biotech Co., Ltd.
    • Sinocelltech Ltd.
    • Shenzhen Shenxin Biotechnology Co., Ltd
    • Starna Therapeutics
    • Blue Lake Biotechnology Inc.
Product Code: TMRGL86639

Respiratory Syncytial Virus Vaccine Market - Scope of Report

TMR's report on the global respiratory syncytial virus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global respiratory syncytial virus vaccine market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global respiratory syncytial virus vaccine market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the respiratory syncytial virus vaccine market.

Market Snapshot
Market Value in 2024US$ 3.7 Bn
Market Value in 2035US$ 15.9 Bn
CAGR13.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global respiratory syncytial virus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global respiratory syncytial virus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory syncytial virus vaccine market.

The report delves into the competitive landscape of the global respiratory syncytial virus vaccine market. Key players operating in the global respiratory syncytial virus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory syncytial virus vaccine market profiled in this report.

Key Questions Answered in global respiratory syncytial virus vaccine Market Report:

  • What is the sales/revenue generated by respiratory syncytial virus vaccine across all regions during the forecast period?
  • What are the opportunities in the global respiratory syncytial virus vaccine market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Respiratory Syncytial Virus Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global respiratory syncytial virus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory syncytial virus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory syncytial virus vaccine market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Respiratory Syncytial Virus Vaccine Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Healthcare Expenditure Data Across Key Countries
  • 5.2. Technological Advancements
  • 5.3. Regulatory Scenario across Key Regions / Countries
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. PESTEL Analysis
  • 5.6. Key Industry Events

6. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Vaccine Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Vaccine Type, 2020-2035
    • 6.3.1. Recombinant/Subunit Vaccines
    • 6.3.2. mAB Injection
    • 6.3.3. mRVaccines
    • 6.3.4. Others
  • 6.4. Market Attractiveness By Vaccine Type

7. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Age Group

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Age Group, 2020-2035
    • 7.3.1. Adults & Geriatrics
    • 7.3.2. Children & Pregnant Mothers
  • 7.4. Market Attractiveness By Age Group

8. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Sales Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Sales Channel, 2020-2035
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Sales Channel

9. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Region

10. North America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 10.2.1. Recombinant/Subunit Vaccines
    • 10.2.2. mAB Injection
    • 10.2.3. mRVaccines
    • 10.2.4. Others
  • 10.3. Market Value Forecast By Age Group, 2020-2035
    • 10.3.1. Adults & Geriatrics
    • 10.3.2. Children & Pregnant Mothers
  • 10.4. Market Value Forecast By Sales Channel, 2020-2035
    • 10.4.1. Retail Pharmacies
    • 10.4.2. Hospital Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast By Country, 2020-2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Vaccine Type
    • 10.6.2. By Age Group
    • 10.6.3. By Sales Channel
    • 10.6.4. By Country

11. Europe Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 11.2.1. Recombinant/Subunit Vaccines
    • 11.2.2. mAB Injection
    • 11.2.3. mRVaccines
    • 11.2.4. Others
  • 11.3. Market Value Forecast By Age Group, 2020-2035
    • 11.3.1. Adults & Geriatrics
    • 11.3.2. Children & Pregnant Mothers
  • 11.4. Market Value Forecast By Sales Channel, 2020-2035
    • 11.4.1. Retail Pharmacies
    • 11.4.2. Hospital Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Vaccine Type
    • 11.6.2. By Age Group
    • 11.6.3. By Sales Channel
    • 11.6.4. By Country / Sub-region

12. Asia Pacific Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 12.2.1. Recombinant/Subunit Vaccines
    • 12.2.2. mAB Injection
    • 12.2.3. mRVaccines
    • 12.2.4. Others
  • 12.3. Market Value Forecast By Age Group, 2020-2035
    • 12.3.1. Adults & Geriatrics
    • 12.3.2. Children & Pregnant Mothers
  • 12.4. Market Value Forecast By Sales Channel, 2020-2035
    • 12.4.1. Retail Pharmacies
    • 12.4.2. Hospital Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Vaccine Type
    • 12.6.2. By Age Group
    • 12.6.3. By Sales Channel
    • 12.6.4. By Country / Sub-region

13. Latin America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 13.2.1. Recombinant/Subunit Vaccines
    • 13.2.2. mAB Injection
    • 13.2.3. mRVaccines
    • 13.2.4. Others
  • 13.3. Market Value Forecast By Age Group, 2020-2035
    • 13.3.1. Adults & Geriatrics
    • 13.3.2. Children & Pregnant Mothers
  • 13.4. Market Value Forecast By Sales Channel, 2020-2035
    • 13.4.1. Retail Pharmacies
    • 13.4.2. Hospital Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Vaccine Type
    • 13.6.2. By Age Group
    • 13.6.3. By Sales Channel
    • 13.6.4. By Country / Sub-region

14. Middle East & Africa Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 14.2.1. Recombinant/Subunit Vaccines
    • 14.2.2. mAB Injection
    • 14.2.3. mRVaccines
    • 14.2.4. Others
  • 14.3. Market Value Forecast By Age Group, 2020-2035
    • 14.3.1. Adults & Geriatrics
    • 14.3.2. Children & Pregnant Mothers
  • 14.4. Market Value Forecast By Sales Channel, 2020-2035
    • 14.4.1. Retail Pharmacies
    • 14.4.2. Hospital Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Vaccine Type
    • 14.6.2. By Age Group
    • 14.6.3. By Sales Channel
    • 14.6.4. By Country / Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. GSK plc
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Moderna, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Pfizer, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Sanofi
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. AstraZeneca
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. MAXVAX Biotechnology Limited
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Guangzhou Patronus Biotech Co., Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Sinocelltech Ltd.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Shenzhen Shenxin Biotechnology Co., Ltd
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Starna Therapeutics
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments
    • 15.3.11. Blue Lake Biotechnology Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments

List of Tables

  • Table 01: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Vaccine Type, 2020-2035
  • Table 02: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 03: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 04: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Region, 2020-2035
  • Table 05: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 06: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 07: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 08: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 09: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 10: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 11: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 12: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 13: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 14: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 15: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 16: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 17: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 18: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 19: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 20: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 21: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 22: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 23: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 24: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035

List of Figures

  • Figure 01: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 02: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 03: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Recombinant / Subunit Vaccines, 2020-2035
  • Figure 04: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by mAB Injection, 2020-2035
  • Figure 05: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by mRNA Vaccines, 2020-2035
  • Figure 06: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Others, 2020-2035
  • Figure 07: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 08: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 09: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Adults & Geriatrics, 2020-2035
  • Figure 10: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Children & Pregnant Mothers, 2020-2035
  • Figure 11: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 12: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 13: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Retail Pharmacies, 2020-2035
  • Figure 14: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Hospital Pharmacies, 2020-2035
  • Figure 15: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Others, 2020-2035
  • Figure 16: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 17: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Region, 2025-2035
  • Figure 18: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 19: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 20: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 21: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 22: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 23: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 24: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 25: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 26: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 27: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 28: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 29: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 30: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 31: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 32: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 33: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 34: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 35: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 36: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 37: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 38: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 39: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 40: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 41: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 42: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 43: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 44: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 45: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 46: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 47: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 48: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 49: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 50: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 51: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 52: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 53: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 54: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 55: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 56: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 57: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 58: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 59: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 60: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 61: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 62: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035